focus -WSS

focus

author：Wikipedia 2025-10-02 00:27:53 - browse：61

Janet Woodcock -- health policy coverage from STAT — Janet Woodcock, the FDA's principal deputy commissioner Chip Somodevilla/Getty Images

WASHINGTON — It’s the end of an era for the Food and Drug Administration’s longtime drug chief, but she’s drawn the battle plans for the agency’s next chapter.

Janet Woodcock joined the FDA’s biologics division in 1986 but soon moved to the drug side, where over nearly three decades, she oversaw hundreds of reviews, new and evolving classes of therapies and several clashes with Congress and patient advocates. In recent years, she also warded off attacks on the agency’s decisionmaking during the Covid-19 pandemic, particularly when the agency veteran took the acting commissioner role during President Biden’s long search for a permanent leader, and took charge of a vast reorganization plan sparked by the baby formula crisis.

Some of those efforts still hang in the balance as she departs this week. Critics argue that under her oversight, the drug division worked too closely with pharmaceutical companies to give broad approvals to new medicines like Biogen’s Aduhelm or so-called accelerated approval to controversial therapies like Sarepta’s Duchenne muscular dystrophy medicine Exondys 51, which is still in the midst of post-marketing studies to prove its effectiveness.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Former reverend arrested for allegedly killing 8

hotspot

WSS

In the gardens at Boston Children's Hospital, families find sanctuary

NIH tests clinical research in primary care with $30 million program

Former reverend arrested for allegedly killing 8

How faith leaders like me can help address America's obesity epidemic

Pharma companies must ensure equitable access to obesity drugs

NIH tests clinical research in primary care with $30 million program

knowledge

focus

leisure time

At least 13 dead in Texas as scorching temps continue

A new crop of companies is reshaping the health data economy

Cancer drug shortages should be causing more outrage

What to watch for from Zogenix and Amicus clinical trials

Cancer drug shortages should be causing more outrage

A new crop of companies is reshaping the health data economy

Sports medicine is finally prioritizing gender equality

Roche’s Alnylam deal shows drug firms interested in heart drugs

How one medical school became remarkably diverse

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

leisure time

Senate panel puts off hardest PBM reforms for another day

Deposition: Sackler embraced plan to conceal OxyContin’s strength

Democrats decry new health bill for going easy on private equity

What it's like to live with paralysis for one psychologist

Will the FTC rein in IQVIA's health data empire?

STAT Report: Patient voices and perspectives

hotspot

entertainment

knowledge

knowledge